Motov S, et al. - Subdissociative intravenous-dose ketamine (SDK) was compared to morphine regarding the analgesic efficacy and safety in geriatric Emergency Department (ED) patients. Researchers undertook a prospective, randomized, double-blind trial evaluating ED patients aged 65 and older experiencing moderate to severe acute abdominal, flank, musculoskeletal, or malignant pain. Findings revealed that for short-term treatment of acute pain, SDK administered at 0.3 mg/kg over 15 min provides analgesic efficacy comparable to morphine but results in higher rates of psychoperceptual adverse effects.